Anti-Human IgD Conjugated Dextran, a breakthrough in targeted drug delivery, provides a very precise and effective way to administer therapy to B cells. It is based on the specificity of dextran, a biocompatible, biodegradable polysaccharide, bound to Anti-Human Immunoglobulin D (IgD) antibodies. Conjugated dextran to these antibodies becomes a tactical vehicle for selective tagging of B cells, which harbor the IgD receptor. Such specificity makes delivery and pharmacokinetic efficacy of therapy agents dramatically enhanced, reducing off-target effects. It is a potential route for treating autoimmune conditions and B cell cancers. A complex branched glucan, dextran is a popular biomedical agent because of its good biocompatibility, water solubleness and modifiable chemical structure. All of which makes dextran a vital drug carrier. Dextran, conjugated to Anti-Human IgD antibodies, provides an impressive platform that targets B cells. B cells are immune cells and the fact that they carry IgD on their surface means they can be a prime candidate for treatment. Conjugate dextran with Anti-Human IgD, and then take advantage of this specificity to send drugs directly to B cells, increasing the therapeutic index of drugs and decreasing toxicity across the body. It is an especially helpful therapeutic in autoimmune conditions and some B-cell tumours, where targeted therapy can dramatically increase patient survival. Anti-Human IgD Conjugated Dextran acts by binds specifically the Anti-IgD antibody structure to the surface of B cell IgD receptors. This binds the dextran-drug complex and allows it to be taken up by receptor-dependent endocytosis into the B cells. The drug is then selectively released into the cell, and so the agents acting on it act where they are most needed. This specific delivery method does not only improve the drug's effectiveness but also minimises side-effects through the reduced contact with target cells. Furthermore, dextran carrier has added advantages including increased duration of time in circulation in blood and saving the drug from early degradationA distinct feature of Anti-Human IgD Conjugated Dextran is that it can revolutionize treatment of autoimmune conditions. It is called autoimmune disease, where the immune system is aversely attacking body tissues through B cells that generate autoantibodies against certain tissues. Systemic immunosuppression is the standard form of treatment for autoimmune conditions and typically has serious side effects and increased infections. The better approach can be found by using anti-human IgD conjugated dextran system. It can target the B cells that produce autoantibodies and suppressing the disease itself but not the immune system at large. This precision medicine model could be used to increase the safety and efficacy of treatment for autoimmune disease and change the clinical landscape for autoimmune diseases like systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis.
Figure 1. IgD conjugated dextran system.
Anti-Human IgD Conjugated Dextran can be used for B cell malignancies including certain lymphomas and leukemia, where chemotherapeutic drugs can be delivered to cancerous B cells. This specificity minimises collateral damage to normal cells and the side-effects that come with chemotherapy. What's more, the conjugated dextran can be loaded with multiple therapeutic molecules, allowing combination therapy to act on multiple pathways of cancer cell survival and proliferation at the same time. Such multi-targeted therapy can improve total therapeutic efficacy and minimize drug resistance in the cancer cells. In addition, dextran's flexibility as a carrier molecule makes it useful for drugs of all kinds – small molecule inhibitors, biologics, nucleic acids. This flexibility makes Anti-Human IgD Conjugated Dextran an open platform to tailor for the requirements of various therapeutic scenarios. For example, in gene therapy, dextran could be mixed with drugs that are made from nucleic acids to get genetic material into B cells, which could then fix the genetic error right there in the beginning. As well, dextran can be injected into B cells to deliver antigens directly to the immune system, offering more potent immunization programmes. The modulation of drug delivery from Anti-Human IgD Conjugated Dextran is accomplished by controlling how the molecules of the drug interact with the structure (non-covalent interaction or stimuli-responsive linkage) that dispenses the drug on specific induced conditions like pH, temperature or enzymatic activity. This multifunctionality is what makes Anti-Human IgD Conjugated Dextran an ideal candidate for building new drug delivery systems with novel properties to address a range of therapeutic needs.
This versatility also makes Anti-Human IgD Conjugated Dextran an ideal platform for novel drug delivery systems with a customised mode of action for different therapeutic applications. So, for example, pH-sensitive links can be engineered to release the drug in acids (like in the tumour tissue or in the intracellular space) and get the drug delivered right to where you need it. Also, because dextran is biodegradable, the structure of the scaffold breaks down into non-toxic byproducts after the drug has been released. This is crucial in drug delivery applications, where the carrier does not become buried inside the body and harm the body. The selection of biocompatible building blocks and linkages can also enhance the overall safety and efficacy of the drug delivery system, making Anti-Human IgD Conjugated Dextran an attractive option for clinical applications. Another significant advantage of Anti-Human IgD Conjugated Dextran is its potential to improve patient compliance and convenience. Traditional drug delivery methods often require frequent dosing and can be associated with considerable side effects, leading to poor patient adherence to treatment regimens. The targeted and controlled release properties of Anti-Human IgD Conjugated Dextran can reduce the frequency of dosing and minimize side effects, making treatments more tolerable and easier to manage for patients. This improved patient compliance can lead to better therapeutic outcomes and overall quality of life for individuals undergoing treatment. So, for example, pH-sensitive linkages can be configured to release the drug when the environment is acidic (tumor tissues, for example, or intracellular compartments), so the drug is dispensed only where it is needed. Furthermore, dextran is biodegradable and so the nanocarriers breaks down into non-toxic residues once the drug is administered. This is especially important for drug delivery because the carrier doesn't get hided in the body and produce side effects. The use of biocompatible building blocks and interconnections can also increase the overall safety and efficacy of the drug delivery system making Anti-Human IgD Conjugated Dextran attractive in clinical use. Another big advantage of Anti-Human IgD Conjugated Dextran is its ability to increase compliance and convenience in patients. In the older form of delivery, it often requires frequent dosages and significant side effects — not good patients sticking to regimens. Because Anti-Human IgD Conjugated Dextran's targeted and controlled release can reduce doses and adverse effects, treatments can be made tolerable and manageable for patients. Such increased patient compliance can result in improved therapy and living conditions for the patients.
Alternate Names:
Dextran-conjugated Anti-Human IgD
Anti-Human IgD-Dextran Conjugate
IgD-specific Dextran Conjugate
Dextran-anti-IgD
Anti-IgD Dextran Conjugate
Anti-Human IgD Immunodextran
Human IgD-targeted Dextran Conjugate
Anti-Human IgD Linked to Dextran
References:
1. Shirai A, et al.; Treatment with dextran-conjugated anti-IgD delays the development of autoimmunity in MRL-lpr/lpr mice. J Immunol. 1994, 153(4):1889-94.
Datasheet
